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Centronuclear myopathies (CNM) are congenital disorders associated with muscle weakness and abnormally 
located nuclei in skeletal muscle. An autosomal dominant form of CNM results from mutations in the gene 
encoding dynamin 2 (DNM2), and loss-of-function mutations in the gene encoding myotubularin (MTM1) 
result in X-linked CNM (XLCNM, also called myotubular myopathy), which promotes severe neonatal hypo-
tonia and early death. Currently, no effective treatments exist for XLCNM. Here, we found increased DNM2 
levels in XLCNM patients and a mouse model of XLCNM (Mtm1–/y). Generation of Mtm1–/y mice that were 
heterozygous for Dnm2 revealed that reduction of DNM2 in XLCNM mice restored life span, whole-body 
strength, and diaphragm function and increased muscle strength. Additionally, classic CNM-associated his-
tological features, including fiber atrophy and nuclei mispositioning, were absent or reduced. Ultrastructur-
al analysis revealed improvement of sarcomere organization and triad structures. Skeletal muscle–specific 
decrease of Dnm2 during embryogenesis or in young mice after disease onset revealed that the rescue asso-
ciated with downregulation of Dnm2 is cell autonomous and is able to stop and potentially revert XLCNM 
progression. These data indicate that MTM1 and DNM2 regulate muscle organization and force through a 
common pathway. Furthermore, despite DNM2 being a key mechanoenzyme, its reduction is beneficial for 
XLCNM and represents a potential therapeutic approach for patients.
Introduction
Centronuclear myopathies (CNM) are a group of congenital 
myopathies characterized by muscle weakness, fiber atrophy, pre-
dominance of type I fibers, and increased centralization of nuclei 
not secondary to muscle regeneration (1, 2). Three main forms of 
CNM have been characterized: X-linked CNM (XLCNM; OMIM 
310400), due to mutations in the phosphoinositides phosphatase 
myotubularin (MTM1) (3); autosomal recessive CNM (ARCNM, 
OMIM 255200), caused by mutations in the membrane remodeling 
protein amphiphysin 2 (BIN1) (4), and autosomal dominant CNM 
(ADCNM, OMIM 160150), due to mutations in dynamin 2 (DNM2) 
(5). The relationship between the implicated genes in muscle is not 
known, and potent therapeutic approaches are lacking.
XLCNM, also called myotubular myopathy, is the most common 
and severe form of CNM, with neonatal onset and a poor progno-
sis (1). To date, more than 200 different mutations in MTM1 have 
been reported in about 450 families, most of which lead to a strong 
reduction of MTM1 protein (6–9). Mtm1-knockout mice or mice 
with knockin of a patient mutation both recapitulate the CNM 
phenotype with classical histological features including abnormal 
organelle positioning, mislocalization of nuclei, and muscle atro-
phy, associated with a corresponding reduction in muscle strength 
(10–12). A defect in triad structures associated with abnormal exci-
tation-contraction coupling has been reported in several animal 
models and patients with various forms of CNM (13–15), identify-
ing a common defect in all CNM forms. This is consistent with a 
proposed role of MTM1 in the regulation of phosphoinositides level 
on the sarcoplasmic reticulum component of the triads (14, 16).
Dynamins are large GTPase proteins that play important roles in 
membrane trafficking and endocytosis (17–20) and in actin cyto-
skeleton assembly (19–21). Dynamins can form polymerized rings 
around membrane tubules (22) and are involved in membrane fis-
sion events (20, 23, 24), providing a paradigm of a mechanoen-
zyme. Three dynamins have been identified in humans: dynamin 1, 
expressed mainly in neurons, dynamin 3, expressed predominantly 
in brain and testis, and DNM2, which is ubiquitously expressed. 
Different heterozygous DNM2 mutations have been identified in 
tissue-specific diseases; ADCNM affecting skeletal muscle (5) and 
autosomal dominant Charcot-Marie-Tooth (CMTDIB, OMIM 
606482) peripheral neuropathy (25).
Recent biochemical studies have indicated that some CNM-
causing DNM2 mutations increase dynamin oligomer stability and 
GTPase activity (26, 27). This was supported in vivo by either knock-
in or overexpression of the most common CNM-DNM2 patient 
mutation in mice, which induced CNM-like features at adulthood 
(28, 29), indicating that the disease is not due to haploinsufficiency. 
Overexpression of WT DNM2 also caused similar CNM-like pertur-
bation to the muscle, albeit to a lesser extent (28, 30).
The main goal of this study was to validate a rescue approach for 
XLCNM. Due to their common implication in CNM, we suspected 
that MTM1 and DNM2 might function in a common pathway, 
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where either MTM1 loss-of-function or DNM2 gain-of-function 
lead to the CNM phenotype. We hypothesized that MTM1 might be 
a negative regulator of DNM2 function in muscle and that reduced 
DNM2 expression in an XLCNM model may rescue the XLCNM 
phenotype. To test this hypothesis, we produced Mtm1–/y mice that 
were heterozygous for DNM2 (Mtm1–/yDnm2+/–). We found that 
reducing DNM2 expression in Mtm1–/y mice is sufficient to rescue 
the early XLCNM lethality and most features of the disease. We 
also showed that reducing DNM2 expression only in muscle from 
embryogenesis, or even after the onset of the disease, was sufficient 
to increase the life span of Mtm1–/y mice. Finally we provide what we 
believe is the first evidence that MTM1 is a regulator of DNM2 in 
skeletal muscle and propose a rationale disease for treatment.
Results
Characterization of Dnm2 heterozygous (Dnm2+/–) mice. Constitutive 
knockout of Dnm2 was previously shown to be lethal early during 
embryogenesis (31). We created Dnm2–/– mice by targeting exon 8 
(Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI71206DS1). From 100 pups, we 
did not identify any Dnm2–/– mice, confirming that Dnm2–/– is 
embryonically lethal. Dnm2+/– pups were identified at expected 
Mendelian ratios and were further analyzed under the EUMODIC 
phenotyping program (32). Basic blood chemistry tests indicated 
no difference between WT and Dnm2+/– mice for urea (indicating 
normal kidney function), calcium (implying osmotic homeosta-
sis), and total cholesterol (suggesting absence of cardiovascular 
disease) levels (Supplemental Figure 2A). Normal ECG measure-
ments suggested unaltered electrical activity in the heart (Supple-
mental Figure 2B). Overall, there was no difference in body weight 
(Supplemental Figure 2C) or in lean tissue or fat content between 
WT and Dnm2+/– mice (Supplemental Figure 2D). An electromy-
ography test for basic muscle function revealed no difference in 
single nerve conduction velocity (Supplemental Figure 2E). Tibia-
lis anterior (TA) muscle mass was similar between WT and Dnm2+/– 
mice (Supplemental Figure 2F), and no difference in absolute or 
specific maximal force or fatigability of the TA was detected (Sup-
plemental Figure 2, G–I), indicating overall that Dnm2+/– mice are 
clinically and physiologically similar to WT mice, with no detect-
able difference in muscle function.
DNM2 levels in XLCNM. Before investigating the therapeutic 
potential of downregulation of DNM2 in XLCNM, we measured 
DNM2 protein levels by Western blot on XLCNM patient muscle 
lysates (Figure 1A). We identified a 1.5-fold increase in DNM2 pro-
tein expression from 5 neonatal XLCNM muscle biopsies tested 
when compared with control age-matched biopsies (Figure 1B). 
Figure 1
DNM2 levels in XLCNM. (A) Representative Western blot of XLCNM patient muscle lysates for DNM2, MTM1, and GAPDH loading control. (B) 
Relative level of DNM2 protein expression determined by densitometry, standardized to GAPDH. n = 5 patients. TA (C) and diaphragm (E) skeletal 
muscle lysates from 5-week-old WT and Mtm1–/y mice were immunoblotted for DNM2 and GAPDH. Relative levels of DNM2 protein determined 
by densitometry of DNM2 immunoreactive polypeptides, standardized to GAPDH, for TA (D) and diaphragm (F). DNM2 expression is represented 
as fold difference from WT lysate. n = 4 mice. (G) Diaphragm muscle sections stained for H&E. Scale bars: 100 μm. All graphs depict mean ± 
SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
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We then determined whether the increase in DNM2 expression 
was also observed in an animal model of XLCNM. In this study, we 
used Mtm1–/y mice that faithfully reproduce XLCNM (10, 15). TA 
muscle lysates from 5-week-old Mtm1–/y mice exhibited a significant 
increase in DNM2 levels compared with WT littermates (Figure 1, C 
and D), suggesting that increased DNM2 is linked to the XLCNM 
phenotype. An increase in DNM2 expression was also observed in 
the diaphragm (Figure 1, E and F), which appeared affected histo-
logically, with more atrophic fibers containing mislocalized nuclei 
(Figure 1G). This finding suggests respiratory insufficiency as a 
cause of death in Mtm1–/y mice, similar to what occurs in patients.
Reducing DNM2 expression greatly prolongs the life span of Mtm1–/y mice. 
Reducing DNM2 at the genetic level to 50% in the Dnm2+/– mice has 
no detectable clinical or physiological effects. To determine wheth-
er reducing DNM2 expression may rescue XLCNM due to MTM1 
mutations, we crossed Mtm1+/– mice with Dnm2+/– mice to produce 
male offspring that were Mtm1–/yDnm2+/–. Most Mtm1–/y mice died 
between 1 and 3 months of age as previously reported (10), whereas 
100% of Mtm1–/yDnm2+/– mice survived for at least 1 year (Figure 2A), 
with no significant difference in body weight compared with WT 
mice (Figure 2B), indicating that reduced expression of DNM2 can 
rescue the early lethality observed in Mtm1–/y mice. Mtm1–/yDnm2+/–
 mice that were not sacrificed reached 2 years of age. At 8 weeks, 
when approximately 60% of Mtm1–/y mice were still alive, Mtm1–/y 
Dnm2+/– mice were not distinguishable from WT mice upon general 
inspection, whereas Mtm1–/y mice displayed a significant decrease in 
movement and activity (Supplemental Video 1).
We determined the level of DNM2 protein expression on 
lysates from several muscles at different ages. In the diaphragm, 
DNM2 levels were reduced approximately 50% in Dnm2+/– and 
Figure 2
Reduced DNM2 expression greatly rescues the life span of Mtm1–/y mice. (A) Life span of all mice, represented as percentage survival. All mice 
in groups WT, Dnm2+/–, and Mtm1–/yDnm2+/– survived to at least 12 months. (B) Mouse whole-body weight. (C–F) Relative level of DNM2 protein 
was determined by densitometry of DNM2 standardized to GAPDH (blots on Supplemental Figure 5). DNM2 level is represented as fold difference 
from WT lysate. Expression was determined in 8-week-old, 16-week-old, and 6-month-old mice from diaphragm (DIA) (C), gastrocnemius (GAS) 
(D), TA (E), and soleus (SOL) (F) muscles. n = 2–8 mice. (G) mRNA levels were quantified by qRT-PCR analysis, with DNM2 levels expressed 
relative to GAPDH. Graph represents 3 independent experiments. Gastrocnemius (H), TA (I), and soleus (J) muscle weights (n = 5–13 mice). All 
graphs depict mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. w, weeks of age; m, months of age.
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Mtm1–/yDnm2+/– mice compared with WT mice, as expected, at 
both 8 weeks and 6 months of age (Figure 2C). Mtm1–/y mice 
exhibited an increase in DNM2 levels in diaphragm compared 
with WT mice at 8 weeks, consistent with results from 5-week-old 
mice (Figure 1F). In the gastrocnemius (Figure 2D), TA (Figure 
2E), and soleus (Figure 2F) muscles, the same trend was seen at 
8 weeks, 16 weeks, and 6 months (Supplemental Figure 5). There-
fore, DNM2 levels are consistently increased in Mtm1–/y mice and 
consistently reduced in Dnm2+/– and Mtm1–/yDnm2+/– mice com-
pared with WT mice in different muscles at different ages.
To determine whether the varied DNM2 protein level is due 
to altered protein synthesis, we performed quantitative RT-PCR 
(qRT-PCR) analysis on 8-week-old TA muscle lysates. The mRNA 
Dnm2 levels in both Dnm2+/– and Mtm1–/yDnm2+/– mice were signif-
icantly reduced compared with WT and Mtm1–/y mice (Figure 2G), 
correlating with DNM2 protein expression (Figure 2E). No sig-
nificant increase was seen in Dnm2 mRNA expression in Mtm1–/y 
muscles, indicating that increased DNM2 protein expression in 
Mtm1–/y muscles may be due to increased stabilization of DNM2 or 
reduced degradation rather than increased transcription.
Figure 3
CNM histological features are greatly rescued in Mtm1–/y mice with reduced DNM2 expression. Transverse TA sections from 8-week-old (A) or 
16-week-old (C) mice were stained with H&E (upper panel) or SDH (lower panel). Scale bars: 300 μm; 25 μm (high magnification). (B) Transverse 
muscle sections from 8-week-old mice viewed by TEM. Arrow indicates membrane accumulation around nucleus. Scale bar: 0.5 μm. Transverse 
TA muscle sections from 8-week-old mice (D) and 16-week-old (E) mice were analyzed for fiber area. Fiber size is grouped into 500-μm² intervals, 
and represented as the percentage of total fibers. n = 5–7 mice. (F) The frequency of fibers with internal or central nuclei was scored. n = 5 mice. 
Internal nuclei are defined as not subsarcolemmal or central. Images were not analyzed in Mtm1–/y mice at 16 weeks, as they usually die before 
this age. All graphs depict mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
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As the TA was one of the most affected muscles in Mtm1–/y mice 
(10, 15), we investigated the localization of MTM1 and DNM2 
by immunofluorescence analysis in TA from 8-week-old mice. 
The Z-line, identified by α-actinin staining, appeared relatively 
undisturbed (Supplemental Figure 3A). DNM2 colocalized with 
α-actinin at the Z-line and appeared relatively unperturbed in 
Mtm1–/y and Mtm1–/yDnm2+/– mice (Supplemental Figure 3A). 
MTM1 was barely detectable in Mtm1–/y and Mtm1–/yDnm2+/– mice, 
as expected (Supplemental Figure 3B). These data show that reduc-
ing expression of DNM2 rescues the life span and body weight of 
Mtm1–/y mice to WT level.
The 3′ UTR region of DNM2 contains a site for miR-133a bind-
ing, resulting in repression of protein expression, and lack of miR-
133a was shown to cause CNM-like features in mice, correspond-
ing with an increase in DNM2 expression (30). qRT-PCR analysis 
performed on 8-week-old TA lysates from Mtm1–/y mice identified 
no significant difference in miR-133a expression (Supplemen-
tal Figure 4A), despite the increase in DNM2 level (Figure 2E). 
miR-133a was, however, significantly increased in Dnm2+/– and Mtm1–/y 
Dnm2+/– mice (Supplemental Figure 4). The 1.5-fold increase in 
miR-133a, however, did not lead to a stronger decrease in DNM2 
level than expected in Dnm2+/– mice (50%, Figure 2E). The molec-
ular mechanisms causing increased miR-133a expression are 
unclear at present.
Muscle atrophy in Mtm1–/y mice is rescued by reducing DNM2 expres-
sion. To analyze further the effect of reducing DNM2 expression in 
Mtm1–/y mice, we measured muscle mass. The fast-twitch gastroc-
nemius muscle was atrophied in Mtm1–/y mice; however, no atro-
phy was observed in Mtm1–/yDnm2+/– mice analyzed at up to 1 year 
of age (Figure 2H). Likewise, other fast-twitch muscles, the exten-
sor digitorum longus (EDL) and plantaris muscle, did not exhibit 
atrophy in Mtm1–/yDnm2+/– mice at up to 1 year of age compared 
with WT mice (Supplemental Figure 4, B and C). The TA showed 
a strong atrophy in Mtm1–/y mice compared with Mtm1–/yDnm2+/–, 
WT, and Dnm2+/– mice at 8 weeks (Figure 2I). Mtm1–/yDnm2+/– TA 
weights were indistinguishable from those of WT mice at this age. 
At 16 weeks, unlike Mtm1–/y mice, Mtm1–/yDnm2+/– mice were still 
alive (Figure 2A) and presented with some TA atrophy compared 
with WT and Dnm2+/– mice, indicating that TA atrophy in Mtm1–/y 
Dnm2+/– is delayed. Interestingly the slow-twitch soleus muscle 
exhibited atrophy in Mtm1–/y mice at 8 weeks, whereas there was no 
atrophy in Mtm1–/yDnm2+/– mice at up to 1 year of age compared 
with WT mice (Figure 2J). Similar results were seen when whole 
muscle mass was measured relative to body weight (Supplemental 
Figure 4, D–F). No difference was observed in liver or heart weights 
between Mtm1–/yDnm2+/– and WT mice (Supplemental Figure 4, G 
and H). Therefore, muscle atrophy was fully rescued in gastrocne-
mius and soleus muscles and strongly delayed in TA muscle fol-
lowing the reduction of DNM2 expression in Mtm1–/y mice.
CNM histology is greatly rescued in Mtm1–/y mice by reducing DNM2 
expression. CNM presents histologically with mislocalized inter-
nal nuclei and muscle fiber hypotrophy. We analyzed 2 main time 
points: early (8 weeks), when the majority of the Mtm1–/y mice 
were still alive, and late (16 weeks), when 95% of Mtm1–/y mice 
have died. At 8 weeks, Mtm1–/y TA muscle exhibited character-
istic mislocalization of nuclei (Figure 3, A and F), reduced fiber 
size (Figure 3, A and D), and abnormal succinate dehydrogenase 
(SDH) staining with subsarcolemmal and central accumulations 
(Figure 3A). Mtm1–/yDnm2+/– TA muscles were histologically simi-
lar to those of WT and Dnm2+/– mice, as observed for the gastroc-
nemius and soleus muscles (Supplemental Figure 4, I and J), with 
only a few abnormal fibers on SDH staining (Figure 3A). Fiber 
hypotrophy was rescued and internal and central nuclei signifi-
cantly reduced compared with Mtm1–/y mice (Figure 3, A, D, and 
F). In addition, membrane accumulations around the nucleus 
were reduced (Figure 3B). By 16 weeks, the TA phenotype from 
Mtm1–/yDnm2+/– mice was mixed, as some areas appeared healthy 
and other areas resembled 8-week-old Mtm1–/y muscle, with mus-
cle fiber hypotrophy, mislocalization of nuclei, and abnormal 
SDH staining (Figure 3, C, E, and F). The localization of desmin, 
an MTM1-binding partner shown to be disrupted in Mtm1–/y mice 
(33), was barely altered in Mtm1–/yDnm2+/– mice (Supplemental 
Figure 6A), indicating that normal desmin localization is restored 
in Mtm1–/yDnm2+/– mice. Overall, these results indicate the CNM 
phenotype in different muscles in Mtm1–/y mice is rescued or 
strongly delayed by reducing DNM2 expression.
Figure 4
Improved muscle strength and endur-
ance of Mtm1–/y mice with reduced 
DNM2 expression. (A) The string test 
was performed on mice weekly from 3 to 
8 weeks. A fall was considered equal to 
20 seconds. (B) The absolute maximal 
force of the TA muscle was measured in 
8-week-old and 16-week-old mice. (C) 
Specific maximal force of the TA. Mtm1–/y 
mice usually die before 16 weeks and 
were therefore not measured at that age. 
(D) Fatigue in TA muscle, measured as 
the time taken to reach 50% of maximum 
muscle force. Muscle fatigue was unable 
to be measured in Mtm1–/y mice at 8 weeks 
due to extreme muscle weakness. All 
graphs depict mean ± SEM. *P < 0.05; 
**P < 0.01; ***P < 0.001. n = minimum 5 
mice per group.
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Reducing DNM2 expression improves muscle strength and perfor-
mance of Mtm1–/y mice. We next determined whether reducing 
DNM2 expression rescues the functional phenotype of Mtm1–/y 
mice. The string test requires mice that are suspended by their 
front paws to lift and hold their hind limbs on the wire. While 
Mtm1–/y mice fell off on several trials and were unable to per-
form the test by 8 weeks, Mtm1–/yDnm2+/– mice performed the 
test similarly to WT and Dnm2+/– mice (Figure 4A and Supple-
mental Videos 2–4), indicating a rescue of whole-body strength. 
At 8 weeks, TA muscles from Mtm1–/y mice exhibited extremely 
weak absolute and specific maximal muscle force, whereas 
Mtm1–/yDnm2+/– mice performed the test similarly to WT and 
Dnm2+/– mice (Figure 4, B and C). At 16 weeks, the maximal force 
of the TA muscle of Mtm1–/yDnm2+/– mice was reduced, consis-
tent with histological data. Furthermore, no change in fatiga-
bility was observed at 8 weeks; however, at 16 weeks, Mtm1–/y 
Dnm2+/– TA muscles fatigued faster than controls (Figure 4D). 
Notably histologically and physiologically, 16-week-old Mtm1–/y 
Dnm2+/– mice performed better than Mtm1–/y mice at 8 weeks, 
indicating either a slower progression of the disease or rescue in 
some but not all muscle fibers, as indicated by the mixed pheno-
type observed histologically in the TA at 16 weeks (Figure 3C). 
Overall, atrophy and decreased muscle force of the TA muscle in 
Mtm1–/yDnm2+/– mice is reduced and strongly delayed compared 
with that of Mtm1–/y mice.
Improved muscle ultrastructure in Mtm1–/yDnm2+/– mice. We next 
analyzed the ultrastructure of Mtm1–/yDnm2+/– muscle by transmis-
sion electron microscopy (TEM). Eight-week-old Mtm1–/yDnm2+/– 
TA morphology resembled that of WT and Dnm2+/– muscles, with 
aligned Z-lines and sarcomeres and no obvious mitochondrial 
structural abnormalities, whereas Mtm1–/y muscle displayed abnor-
mal mitochondria shape, membrane accumulations, Z-line mis-
alignment, and altered myofibrillar width (Figure 5A), as reported 
previously (10, 15, 34). Notably, muscle from Mtm1–/yDnm2+/– mice 
at 16 weeks was heterogeneous; some regions appeared healthy, 
while other areas appeared disturbed (Figure 5B). Furthermore, 
mitochondrial abnormalities that were not evident at 8 weeks were 
detectable in some regions of 16-week-old Mtm1–/yDnm2+/– mice. 
This supports our previous histological and physiological results, 
indicating that the CNM phenotype in Mtm1–/yDnm2+/– TA muscle 
is partially albeit substantially rescued at different time points.
Triad structures are normalized in Mtm1–/yDnm2+/– mice. A com-
mon feature shared between CNM patients and animal models of 
CNM is a disruption of the structure and position of triads within 
skeletal muscle (13–15, 35). DHPRα, a voltage-dependent calcium 
channel found on T-tubules of mature muscles, was localized in 
punctuate structures within TA myofibers of WT, Dnm2+/–, and 
Mtm1–/yDnm2+/– mice, consistent with normal T-tubule localiza-
tion (Supplemental Figure 6B). However, in Mtm1–/y muscle, this 
specific staining was lost, indicating severe disruption of the 
T-tubules. This was confirmed by staining for ryanodine recep-
tor (RyR1), a calcium channel localized specifically at the sarco-
plasmic reticulum of triads. Transverse and longitudinal images 
showed a rescue of RyR1 localization in most fibers from Mtm1–/y 
Dnm2+/– mice, with only a few fibers exhibiting RyR1 accumula-
tions or perturbed localization, as seen extensively in Mtm1–/y mice 
(Figure 6A). High-magnification TEM images confirmed strong 
disruption of T-tubule/triad structures in Mtm1–/y mice compared 
with WT and Dnm2+/– mice, whereas well-positioned triads were 
clearly visible in Mtm1–/yDnm2+/– mice (Figure 6B). Analysis of the 
triads confirmed no difference in the number of triads per sarco-
mere in WT, Dnm2+/–, or Mtm1–/yDnm2+/– mice, whereas Mtm1–/y 
mice exhibited a reduced number of triads per sarcomere (Figure 
6C), as shown previously (34). Caveolin 3 is found at T-tubules 
during muscle development and regeneration and at the sarco-
lemma in mature muscle (36). While WT and Dnm2+/– muscle 
showed caveolin 3 localizing to the sarcolemma as expected, many 
fibers from Mtm1–/y mice exhibited a strong internal staining pat-
tern of caveolin 3 (Figure 6D). This phenotype was largely rescued 
in Mtm1–/yDnm2+/– muscle, with only occasional fibers showing 
internal localization of caveolin 3. Therefore, the localization and 
structure of triads was rescued in 8-week-old Mtm1–/yDnm2+/– mice.
Long-term physiological phenotype of Mtm1–/yDnm2+/– mice. XLCNM 
presents with very severe muscle weakness in patients and lethal-
ity in Mtm1–/y mice within 1 to 3 months; however, reducing 
DNM2 expression in these mice rescued the life span and greatly 
improved muscle strength at 8 and 16 weeks. We determined the 
phenotype of Mtm1–/yDnm2+/– mice at later time points to assess 
the extent of muscle function compatible with a normal life 
span. Mtm1–/yDnm2+/– mice aged 6 months and 12 months were 
able to move and perform basic tasks (Supplemental Video 5). 
Aged Mtm1–/yDnm2+/– mice looked similar to WT mice (Figure 
Figure 5
Improved muscle ultrastructure of Mtm1–/y mice with reduced DNM2 
expression. TA muscles from 8-week-old (A) and 16-week-old (B) mice 
were imaged by TEM. Scale bars: 0.5 μm (A); 1 μm (B).
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7A), but walked with hind feet pointing outwards (Figure 7B and 
Supplemental Figure 7A). This feature was not progressive from 
6 to 12 months. To determine overall maximal leg strength, the 
grip-strength test was performed using a dynamometer. No dif-
ference in strength of the 2 front paws was observed between WT 
and Mtm1–/yDnm2+/– mice during the first 12 months (Supple-
mental Figure 7B). A small reduction in strength was observed 
in Mtm1–/yDnm2+/– mice compared with WT mice when all 4 
Figure 6
Integrity of triads in TA muscle from 8-week-old mice. (A) Transverse and longitudinal muscle sections were stained with RyR1 or costained with 
RyR1 (green) and α-actinin (red) antibodies and imaged by confocal microscopy. Scale bars: 20 μm (transverse); 5 μm (longitudinal). (B) Muscles 
were imaged by TEM. Arrows point to normally localized triads, shown in high magnification insert. Scale bars: 200 nm; 100 nm (high magnifica-
tion). (C) Percentage of triads visualized per sarcomere. Graph depicts mean ± SEM. *P < 0.05. (D) Transverse muscle sections were stained 
with caveolin 3 and imaged by confocal microscopy. Scale bars: 50 μm.
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paws were measured, at both 6 months and 12 months (Figure 
7C), indicating the hind limbs of Mtm1–/yDnm2+/– mice exhibit 
reduced maximal muscle force compared with WT mice, which 
was not progressive. The rotarod test for general motor coor-
dination, strength, and endurance was performed, with no 
difference observed at 6 or 12 months (Figure 7D), confirm-
ing the general coordination and overall strength of Mtm1–/y 
Dnm2+/– mice was not severely perturbed. The hanging test is a 
Figure 7
Long-term phenotype of Mtm1–/y mice with reduced DNM2 expression. (A) 12-month-old WT (left) and Mtm1–/yDnm2+/– (right) mice. (B) Footprint test 
indicating the angle of hind foot position. Raw data in Supplemental Figure 7. (C) Four-paw grip test. (D) Rotarod test performed under acceleration 
mode (4–40 rpm in 5 minutes). n = 3 trials/mouse/d. (E) The hanging test requires mice to be suspended from a cage lid for up to 60 seconds. n = 3 
trials/mouse (F) A plethysmograph test for resting breathing measurements was performed on 6-month-old mice. Inspiratory/expiratory/relaxation 
time, and breathing frequency are shown; complementary results in Supplemental Figure 8. (G) Maximal muscle force was measured in diaphragm 
from 6-month-old mice. Force-frequency relationship and specific maximal force under twitch and tetanus (100 Hz) are depicted. (H) Longitudinal dia-
phragm sections were stained with H&E. Scale bars: 100 μm. All graphs depict mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. n = minimum 5 mice.
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strenuous test that requires mice to be suspended from a cage lid 
for 60 seconds. The severely affected Mtm1–/y mice were unable to 
perform this test after 1 month (Figure 7E). In comparison, Mtm1–/y 
Dnm2+/– mice could perform this test up to the last age tested (12 
months), albeit to a lesser extent than WT mice (Figure 7E and 
Supplemental Videos 6–8). As Mtm1–/yDnm2+/– mice were able to 
successfully perform basic motor strength tests at up to 12 months 
of age, we conclude that the disease progression was stopped over 
time and life span and basic motor function were rescued.
Normal long-term diaphragm function in Mtm1–/yDnm2+/– mice. We 
have shown that individual muscles appear to be differently affect-
ed in Mtm1–/y mice, and the corresponding rescue by reduction of 
DNM2 is varied between muscles (Figure 2, C–J, and Supplemen-
tal Figure 4). The main concern for the longevity of patients with 
XLCNM is the diaphragm’s function, as they have life-threatening 
respiratory failure (1). In addition, we found the histology of the 
diaphragm in 5-week-old Mtm1–/y mice was strongly altered (Figure 
1G). We thus tested the function of the diaphragm in 6-month-old 
Figure 8
Reducing DNM2 in skeletal muscle alone ameliorates the life span and pathology of Mtm1–/y mice. (A) Life span of all mice represented as a 
percentage of survival. Mtm1–/y mice with reduced DNM2 in muscle depicted as Mtm1–/yDnm2skm+/–. (B) Body weight. (C) Weight of gastrocne-
mius, TA, and soleus muscles as a percentage of total body weight. (D) Transverse TA sections were stained with H&E (top panel) or SDH (lower 
panel). Scale bars: 100 μm. (E) Transverse sections were analyzed for fiber area. Fiber size is grouped into 500 μm² intervals, and represented 
as a percentage of total fibers. (F) The frequency of fibers with internal or central nuclei was counted in TA muscle. (G) Relative level of DNM2 
protein from TA muscles, standardized to GAPDH. DNM2 level is represented as a fold difference from WT lysate. All graphs depict mean + SEM. 
*P < 0.05; ***P < 0.001. n = 4–12 mice, aged 16 weeks.
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DNM2 protein levels at 6 months (Figure 2C), compared with 
Mtm1–/y mice in which DNM2 expression was elevated at 5 weeks 
(Figure 1, E and F) and 8 weeks (Figure 2C). Overall, the diaphragm 
muscle of Mtm1–/yDnm2+/– mice was indistinguishable from that of 
control mice, supporting the extensive phenotypic amelioration of 
the XLCNM phenotypes upon DNM2 reduction.
Muscle-specific reduction of DNM2 is sufficient to rescue the phenotype and 
improve the life span in Mtm1–/y mice. In this study, we were able to fully res-
cue the life span of Mtm1–/y mice and most of the clinical and histologi-
cal features of the disease by reducing DNM2 expression in utero in all 
mice using the plethysmograph test to measure the spontaneous 
breathing pattern under resting conditions. Mtm1–/yDnm2+/– mice 
performed similarly to WT and Dnm2+/– mice, with no significant 
difference detected (Figure 7F and Supplemental Figure 8). No sig-
nificant difference in the force-frequency relationship was detected 
in isolated strips of diaphragm; however, a reduction in specific 
maximal force was observed (Figure 7G). Histologically, Mtm1–/y 
Dnm2+/– diaphragm resembled that of WT and Dnm2+/– muscle, with 
no major alterations to nuclei positioning or fibrosis observed (Fig-
ure 7H). The diaphragm of Mtm1–/yDnm2+/– mice sustained reduced 
Figure 9
Reducing DNM2 in skeletal muscle after the onset of symptoms ameliorates the life span and pathology of Mtm1–/y mice. (A) Life span of all mice 
represented as a percentage of survival. (B) Body weight. (C) Weight of gastrocnemius, TA, and soleus muscles represented as a percentage 
of total body weight. (D) Transverse TA sections were stained with H&E (top panel) or SDH (lower panel). Scale bars: 100 μm. (E) Transverse 
sections were analyzed for fiber area. Fiber size is grouped into 500 μm² intervals. (F) The frequency of fibers with internal or central nuclei were 
counted. (G) Relative level of DNM2 protein from TA muscles, standardized to GAPDH. DNM2 level is represented as a fold difference from WT 
control lysate. All graphs depict mean + SEM. *P < 0.05; **P < 0.01; ***P < 0.001. n = 4–12 mice, aged 16 weeks.
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recombinase. The increased DNM2 expression in the diaphragm 
at 16 weeks may be correlated with the reduced survival rate in 
Mtm1–/yDnm2(i)skm+/– mice from 8 to 16 weeks. Therefore, we con-
clude that reduction of DNM2 levels in muscle after birth, after 
the onset of symptoms, is sufficient to improve the life span and 
the CNM phenotype observed in Mtm1–/y mice.
Discussion
In this study we showed that reducing DNM2 in Mtm1–/y mice res-
cues most features of XLCNM and greatly prolongs life span and 
long-term muscle and motor performance. Furthermore, reduction 
of DNM2 in muscle alone, and after the onset of symptoms, is suf-
ficient to rescue the phenotype.
DNM2 and MTM1 function in a common pathway. Loss-of-function 
mutations in MTM1 and dominant mutations in DNM2 lead 
to CNM in human and CNM phenotypes in mice models (1, 9). 
Moreover, biochemical analysis suggests several DNM2 CNM 
mutants increase DNM2 GTPase activity and oligomerization 
(26, 27). Furthermore, overexpression of WT DNM2 by AAV or 
by miR-133a inhibition resulting in increased DNM2 expression 
promoted muscle defects and centralization of nuclei in mouse 
muscle (28, 30). We thus hypothesized DNM2-CNM mutations 
are gain-of-function. However, no link between MTM1 and DNM2 
functions was previously established. As lowering the genetic dos-
age of DNM2, either systemically or in skeletal muscle, strongly 
ameliorated the XLCNM phenotype of Mtm1–/y mice, we have iden-
tified MTM1 and DNM2 as being linked specifically in muscle, 
in a common pathway controlling muscle mass and maximal 
force. Moreover, we suggest MTM1 is a negative regulator of the 
DNM2 pathway in muscle, as decreased DNM2 can compensate 
for absence of MTM1.
These data represent a first link between MTM1 and DNM2 in 
the pathogenesis of CNM. Moreover, the rescue data presented 
here support that DNM2-CNM mutations are gain-of-function 
in skeletal muscle. We thus hypothesize that several forms of 
CNM are due to increased expression and/or function of DNM2. 
In particular, MTM1 loss in mice, and potentially in human, may 
lead to CNM phenotypes through overexpression and/or over-
activation of DNM2.
Interestingly, we noted increased DNM2 protein expression in 
XLCNM patients and in Mtm1–/y muscle (Figure 1), supporting the 
hypothesis that increased DNM2 levels lead in part to the CNM 
phenotypes. No significant increase was observed in Dnm2 mRNA 
in Mtm1–/y muscle, indicating that the increase in DNM2 protein 
expression is due to either increased stability of the protein or 
reduced degradation. While genetic deletion of a Dnm2 allele led to 
a 50% decrease at the protein level in Dnm2+/– mice, we noted differ-
ent DNM2 levels depending on the muscles investigated, following 
the same genetic deletion in the Mtm1–/y mice. DNM2 protein lev-
els were monitored at 50% of WT levels in the diaphragm (Figure 
2C) and 70% in TA muscles of Mtm1–/yDnm2+/– mice at 16 weeks 
(Figure 2E), and between 130% and 170% in Mtm1–/yDnm2skm+/– and 
Mtm1–/yDnm2(i)skm+/– TA muscles (Figures 8 and 9). Importantly, 
the DNM2 levels correlated with the alteration of these muscles, as 
assessed by histology. As Mtm1–/y mice died before this age, data for 
this genotype were not available, but we noted a consistent DNM2 
increase in all muscles tested in 8-week-old Mtm1–/y mice. Thus 
these data sustain the hypothesis that increased DNM2 levels led 
in part to the CNM phenotype and that decrease or normalization 
of DNM2 levels rescues the XLCNM phenotype.
tissues. To determine whether the rescue of the muscle phenotype was 
cell-autonomous, we crossed HSA-Cre (where HSA indicates human 
skeletal muscle α-actin) and HSA Cre-ERT2 mice (37) with floxed Dnm2 
mice to produce Dnm2skm+/– (Cre positive) and Dnm2(i)skm+/– (Cre-ERT2) 
mice. These mice were then crossed with Mtm1–/y mice to produce 
tissue-specific excision of Dnm2. When DNM2 expression was reduced 
in muscle (Mtm1–/yDnm2skm+/–, HSA promoter active from 9 dpc; ref. 38), 
we were able to increase the life span of Mtm1–/yDnm2skm+/– mice, with 
75% surviving until at least 16 weeks, while no Mtm1–/y mice survived to 
this age (Figure 8A), consistent with our results from Mtm1–/yDnm2+/– 
mice (Figure 2A). Four WT and 4 Mtm1–/yDnm2skm+/– mice have been 
kept alive for future long-term analysis, and all mice were 12 months 
old at the time of publication. A corresponding increase in body weight 
was also observed in Mtm1–/yDnm2skm+/– mice compared with Mtm1–/y 
mice (Figure 8B). No difference in mass of the gastrocnemius or soleus 
muscles was observed between Mtm1–/yDnm2skm+/– and WT mice (Fig-
ure 8C). At 16 weeks, when all Mtm1–/y littermates had died, the TA 
of Mtm1–/yDnm2skm+/– mice exhibited some atrophy, with a reduction 
in muscle mass and fiber size compared with WT littermates, associ-
ated with increased central and internal nuclei and some abnormal 
SDH staining (Figure 8, D–F), similar to that seen in the TA muscle 
from 16-week-old Mtm1–/yDnm2+/– mice (Figure 2). These alterations 
were less pronounced than those seen in Mtm1–/y mice at 8 weeks. 
Importantly, the gastrocnemius and soleus of Mtm1–/yDnm2skm+/– mice 
did not exhibit a significant difference in fiber size or nuclei position 
compared with WT mice (Supplemental Figure 9, A–D), indicating the 
phenotype is rescued differently in different muscles. DNM2 protein 
levels were measured in different muscles at 16 weeks, and there was a 
significant reduction in DNM2 expression in the diaphragm, but not 
in other muscles measured, compared with WT (Figure 8G and Sup-
plemental Figure 9, E–H). Importantly, Mtm1–/y mice were not alive at 
this age to compare the levels of DNM2, which were already increased 
in these muscles at younger ages (Figure 2). As the diaphragm is a 
vital muscle required for breathing, we propose that reduced DNM2 
expression in the diaphragm muscle is critical for increased survival of 
Mtm1–/yDnm2skm+/– mice and to rescue XLCNM.
Muscle-specific reduction of DNM2 after birth is sufficient to rescue 
Mtm1–/y mice. We crossed Mtm1–/y mice with Dnm2+/– mice under 
the HSA-Cre ERT2 system to allow excision of DNM2 after birth in 
muscle, induced by tamoxifen injection (37). Importantly, tamoxi-
fen injections were performed when mice were 3 weeks old, after 
the onset of muscle atrophy (Figure 2) and centralized nuclei (15). 
We found that 70% of the injected Mtm1–/yDnm2(i)skm+/– mice sur-
vived to 16 weeks (Figure 9A). A higher body weight was observed 
compared with that of Mtm1–/y mice; however at 16 weeks, body 
weight was still significantly reduced compared with that of WT 
mice (Figure 9B). No difference in normalized mass of the gas-
trocnemius, soleus, or TA muscles was observed compared with 
WT mice at 16 weeks (Figure 9C), unlike Mtm1–/y mice at ear-
lier time points (Figure 2). Further analysis of TA muscles from 
Mtm1–/yDnm2(i)skm+/– mice showed some fiber hypotrophy (Figure 
9, D and E), associated with increased central and internal nuclei, 
and abnormal SDH staining (Figure 9, D and F), similar to the 
TA muscle from 16-week-old Mtm1–/yDnm2+/– (Figure 3). We noted 
a decrease in DNM2 protein expression in gastrocnemius from 
Mtm1–/yDnm2(i)skm+/– mice at 16 weeks compared with WT mice; 
however, an increase in DNM2 protein expression was observed 
in TA and diaphragm muscles (Figure 9G and Supplemental Fig-
ure 10). These differences may be due to differential efficiency in 
DNM2 excision upon tamoxifen-mediated activation of the Cre 
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of some CNM symptoms was sufficient to improve life span and 
muscle weight in Mtm1–/y mice. Thus, decreasing DNM2 levels after 
birth appears sufficient to revert the deterioration of muscle his-
tology and progression of the disease. This is indeed an important 
advantage for potential application of similar strategies in patients. 
To translate this proof-of-concept toward clinical trials, targeted 
downregulation of DNM2 or drugs inhibiting DNM2 function will 
have to be validated. Compounds inhibiting the function of DNM2 
may be valuable for this aim, assuming their delivery and biodis-
ponibility in skeletal muscle is effective. In conclusion, we have iden-
tified DNM2 as a potential therapeutic target for XLCNM.
Methods
An expanded Methods section can be found in the Supplemental Methods.
Generation of Dnm2 heterozygous mice
The targeting vector was created with LoxP sites flanking exon 8 of Dnm2 
(Supplemental Figure 1), then linearized, and electroporated into ES 
cells. Recombinant ES cells were injected into C57BL/6 blastocysts that 
were implanted in pseudopregnant females and germline transmission 
determined. Mice bred and analyzed were 129pas strain (CMV promoter). 
HSA-Cre C57BL/6 and HSA Cre-ERT2 mice were a kind gift from Daniel 
Metzger (IGBMC) (37, 38) and were used to produce mice with muscle-
specific reduction of DNM2.
Generation of Mtm1–/yDnm2 heterozygous mice
Female Mtm1+/– mice (129pas strain) (10, 15) were bred with male Dnm2 
heterozygous mice to produce 4 possible genotypes in male offspring: 
Mtm1+/yDnm2+/+ (WT); Mtm1+/yDnm2+/– (Dnm2+/–); Mtm1–/yDnm2+/+ (Mtm1–/y); 
and Mtm1–/yDnm2+/–. All mice analyzed in this study were male.
Animal experiments
Animals were housed in a temperature-controlled room (19–22°C) with a 
12-hour light/12-hour dark cycle. Mice were humanely sacrificed by CO2 
inhalation followed by cervical dislocation, according to national and 
European legislation on animal experimentation. Muscles and other tis-
sues were dissected and frozen in nitrogen-cooled isopentane and liquid 
nitrogen for histological and immunoblot assays, respectively.
Phenotyping of Dnm2+/– mice
Dnm2+/– male and female mice aged 10 to 15 weeks were phenotyped under 
the EUMODIC phenotyping program (see Supplemental Methods).
String, grip, hanging, rotarod, and footprint tests
String test. Mice were suspended on a wire by their forelimbs and allowed 20 
seconds to climb, bringing their hind limbs onto the wire.
Grip test. Maximal strength measured from 2 or 4 paws using a dyna-
mometer (Bioseb).
Hanging test. Mice were suspended from a cage lid for a maximum of 60 
seconds, and the time the mouse fell off the cage was recorded.
Rotarod test. Coordination and whole-body muscle strength and fatigabil-
ity were tested using an accelerated rotating rod test (Panlab).
Footprint test. The angle of the hind limbs was measured by analyzing the 
footprint pattern using the ImageJ analysis program (n = 5–8 mice per group).
Plethysmograph measurements
The spontaneous breathing pattern in nonrestrained unstimulated mice 
was measured using a whole-body barometric plethysmograph (EMKA 
Technologies) at the Institut Clinique de la Souris (ICS) (Illkirch, France) 
(n = 3–5 mice per group).
It was recently shown that increased flexibility of dynamin togeth-
er with the tilting of the membrane-inserted pleckstrin homology 
(PH) domain is a prerequisite for normal membrane fission (39). In 
ADCNM, DNM2 mutations are mostly clustered at the interface 
between the middle and PH domains (24, 40), suggesting they affect 
the stability of a closed conformation and lead to increased flexibil-
ity of this region, tilting of the PH domain, and membrane fission 
(24). Overactivation of dynamin-mediated membrane fission either 
by mutations or increased DNM2 levels may thus alter the proper 
balance for membrane remodeling. While T-tubule defects are a 
hallmark of CNM and thus regulation of membrane tubulation at 
this site a tempting hypothesis for explaining the MTM1/DNM2 
pathway, dynamin was never observed on T-tubules in normal adult 
muscle (28, 29). At the physiological level, decreased DNM2 strongly 
reduced or delayed signs of CNM in Mtm1–/y mice, including muscle 
mass, maximal force, and triad and nuclei positioning. This indicates 
a role for endogenous DNM2 in these different processes. Future 
studies will need to address the site of action of DNM2 in muscle.
DNM2 reduction as a potential therapy for XLCNM. We identify here 
a cross-therapy strategy, whereby we downregulate a CNM gene 
(DNM2) to rescue the severe phenotype due to a downregulation 
of another CNM gene (MTM1). This technique differs from thera-
peutic strategies that aim to compensate for the lack of a protein 
by reexpression of the corresponding gene or overexpression of a 
homolog or by modification of the mutated gene to create a func-
tional protein (such as exon skipping).
A main goal of this study was to validate a rescue approach for 
XLCNM. We first reduced DNM2 levels during embryogenesis in 
all tissues of the Mtm1–/y mice; this experimental setup led to an 
extensive delay in the appearance of CNM phenotypes, a strong 
amelioration of motor behavior, and a normal life span, while 
Mtm1–/y mice died mostly in the first 2 months from progressive 
muscle weakness.
Both total and muscle-specific Mtm1–/y induced CNM pheno-
types in mice, indicating XLCNM arises from a primary defect in 
skeletal muscle (10). We obtained a phenotypic rescue of XLCNM 
in Mtm1–/y mice by reducing DNM2 levels specifically in skeletal 
muscle, supporting the concept that XLCNM derives from a prima-
ry skeletal muscle defect and that specific treatment of muscle will 
be enough to ameliorate this disease in humans. In addition, our 
rescue data strongly support that rescuing myofiber intracellular 
organization, including myofibril organization, triad structure, 
and to some extent, nuclei positioning has a direct beneficial out-
come on muscle function and life span and sustain the idea that 
these defects are primary causes of the XLCNM pathology.
However, muscle-restricted downregulation of DNM2 from 
embryonic stages or from 3-week-old mice rescued only 70%–75% of 
mice, compared with 100% rescue of the Mtm1–/yDnm2+/– mice. Mus-
cle-specific knockdown of DNM2 may not be sufficient to rescue all 
Mtm1–/y mice if other organs are also affected. The HSA promoter is 
expressed differently in different fiber types, with highest expression 
in type IIB fibers (41), whereas a key feature of CNM is increased 
type 1 fibers, which may account for the reduced survival rate.
Unlike the Mtm1–/y mice, in which motor behavior of neonates 
appears normal and deteriorates from 2 to 3 weeks of age, followed 
by a rapid progressive muscle weakness, patients are born with a 
severe hypotonia and muscle weakness that do not appear progres-
sive. In addition, several reports indicate decreased fetal movements. 
Using time-inducible heterozygous deletion of DNM2, we found 
decreasing DNM2 expression after birth and after the appearance 
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Microscopy and statistical analysis
All microscopy was performed at the IGBMC Imaging Centre. All sam-
ples for microscopy were mounted in Fluorsave reagent (Merck). Light 
microscopy was performed using a fluorescence microscope (DM4000; 
Leica Microsystems) fitted with a color CCD camera (CoolSNAP cf color; 
Photometrics). Confocal microscopy was performed using a confocal laser-
scanning microscope (TCS SP2 or SP5; Leica Microsystems). ImageJ and 
FIJI analysis software were used for image analysis. Statistical analysis was 
performed using the unpaired Student’s t test (2-tailed) unless stated oth-
erwise. P < 0.05 was considered significant.
Study approval
Animal experimentation was approved by the institutional ethical com-
mittee Com’Eth IGBMC-ICS (2012-128). All human biopsies were taken 
after informed consent was obtained. The use of patient biopsies for 
this study was authorized by the ethical committee of Pitié-Salpêtrière 
Hospital (CCPPRB).
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TA and diaphragm muscle contractile properties
TA muscle force measurements were evaluated by measuring in situ mus-
cle isometric contraction in response to nerve and muscle stimulation 
(n = 5–11 mice per group). Isometric contraction was assessed on muscle 
strips from the ventral part of the costal diaphragm (n = 3–5 mice per group).
Western blotting
Western blotting was performed as described previously (28). Primary anti-
bodies were as follows: home-made DNM2-R2680 (1:500), DNM2-R2865 
(1:500), MTM1-R2827 (1:500), and GAPDH (1:10,000, MAB374; Chemi-
con); secondary antibodies were as follows: anti-rabbit HRP or anti-mouse 
HRP (1:10,000, Jackson ImmunoResearch Laboratories).
qRT-PCR
Total RNA was extracted from 8-week-old TA muscle lysates using Tri 
reagent (Molecular Research Center), reverse transcribed, and amplified 
using Oligo dT primers. Real-time qRT-PCR was performed using a Light-
cycler 480 (Roche Diagnostics) with DNM2 primers (forward, CCAA-
CAAAGGCATCTCCCCT; reverse, TGGTGAGTAGACCCGAAGGT) and 
GAPDH primers as a standard, with the SYBR Green 1 Master kit (Roche 
Diagnostics). Results were standardized to GAPDH (n = 2–3 mice per 
group, performed in triplicate).
Histology and immunofluorescence
Longitudinal and transverse cryosections (8 μm) of mouse skeletal 
muscles were prepared, fixed, and stained with the indicated antibodies 
and viewed using a laser-scanning confocal microscope (TCS SP5; Leica 
Microsystems). H&E and SDH sections were imaged with a slide scanner 
NanoZoomer 2HT equipped with the fluorescence module L11600-21 
(Hamamatsu Photonics). Cross-sectional area (CSA) and nuclei position 
were analyzed in H&E sections from TA mouse skeletal muscle, using FIJI 
image analysis software (n = 4–7 mice per group).
TEM
TEM was performed on TA muscle biopsies as described previously (10, 28). 
The ratio of triads to sarcomere was calculated as described previously (34).
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